These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16970918)
1. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells. Lee K; Wang T; Paszczynski AJ; Daoud SS Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918 [TBL] [Abstract][Full Text] [Related]
2. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122 [TBL] [Abstract][Full Text] [Related]
3. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Liang Y; Besch-Williford C; Hyder SM Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255 [TBL] [Abstract][Full Text] [Related]
4. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Wang T; Lee K; Rehman A; Daoud SS Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036 [TBL] [Abstract][Full Text] [Related]
5. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells. Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545 [TBL] [Abstract][Full Text] [Related]
6. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886 [TBL] [Abstract][Full Text] [Related]
7. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247 [TBL] [Abstract][Full Text] [Related]
8. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392 [TBL] [Abstract][Full Text] [Related]
9. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. Orue A; Chavez V; Strasberg-Rieber M; Rieber M BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474 [TBL] [Abstract][Full Text] [Related]
10. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036 [TBL] [Abstract][Full Text] [Related]
11. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598 [TBL] [Abstract][Full Text] [Related]
12. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc. Farhadi E; Safa M; Sharifi AM; Bashash D Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348 [TBL] [Abstract][Full Text] [Related]
13. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Liang Y; Besch-Williford C; Benakanakere I; Hyder SM Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308 [TBL] [Abstract][Full Text] [Related]
14. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389 [TBL] [Abstract][Full Text] [Related]
16. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106 [TBL] [Abstract][Full Text] [Related]
17. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488 [TBL] [Abstract][Full Text] [Related]
18. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis. Cory AH; Chen J; Cory JG Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536 [TBL] [Abstract][Full Text] [Related]
19. Antitumor Effects of PRIMA-1 and PRIMA-1 Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G Cells; 2021 Jan; 10(1):. PubMed ID: 33430525 [TBL] [Abstract][Full Text] [Related]